Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Showing of Streams
9:40am - 10:20am

Morning Coffee and Networking

More
Showing of Streams
12:35pm - 1:35pm

Networking Luncheon in the Poster & Exhibition Hall

More
Showing of Streams
3:10pm - 3:40pm

Afternoon Coffee Break

More
Showing of Streams
5:30pm - 6:30pm

End of Conference Sessions for the Day

More
6:30pm - 7:30pm
Info

Biotech Week Boston Festival Party @ Royale

Don’t miss the Biotech Week Boston Festival Party at The Royale nightclub. This is the only event where you can kick back, and meet attendees from ALL of the official events that are part of Biotech Week Boston. Unwind, network in a fun atmosphere, and enjoy an evening of rock and roll, complete with a headline band.

*This event is free-to-attend for all registered attendees, however space is limited and available on a first-come, first-serve basis.

More
8:00am - 8:10am 10 mins
Cell and Gene Therapy Bioprocessing
Chairperson's Opening Remarks
  • Charles Sardonini - Director, Process Engineering/Development, Genzyme
8:00am - 8:10am 10 mins
Cell and Gene Therapy Commercialization
Chairperson's Opening Remarks
  • Charles Sardonini - Director, Process Engineering/Development, Genzyme
8:00am - 8:10am 10 mins
Pre-clinical and Clinical Development for Cell and Gene Therapies
Chairperson's Opening Remarks
  • Charles Sardonini - Director, Process Engineering/Development, Genzyme
8:10am - 8:55am 45 mins
Cell and Gene Therapy Bioprocessing
Developing and Implementing a Commercially Viable Integrated and Continuous Process
  • Jason Walther PhD - Principal Scientist, Downstream Bioprocess Development, Sanofi
8:10am - 8:55am 45 mins
Cell and Gene Therapy Commercialization
Developing and Implementing a Commercially Viable Integrated and Continuous Process
  • Jason Walther PhD - Principal Scientist, Downstream Bioprocess Development, Sanofi
8:10am - 8:55am 45 mins
Pre-clinical and Clinical Development for Cell and Gene Therapies
Developing and Implementing a Commercially Viable Integrated and Continuous Process
  • Jason Walther PhD - Principal Scientist, Downstream Bioprocess Development, Sanofi
8:55am - 9:40am 45 mins
Info
Cell and Gene Therapy Bioprocessing
Bioprocessing 4.0 – Digital Technologies Are Transforming Biologics Manufacturing
  • Thomas Seewoester, PhD - Executive Director, Plant Manager, Biogen

Manufacturing processes for biologics have been optimized for the last 100 years. Revolutionary steps in the last 20 years included the introduction of process platforms for monoclonal antibodies, the perfection of large scale fed-batch processes and recently more economic scale-out approaches in single-use systems. Digital technologies in contrast are following a much more rapid and exponential innovation curve. Understanding and leveraging digital technologies, looking beyond the molecule and refining mountains of data into instantaneously and globally available insights and wisdom will be a differentiating factor that is starting to transform our industry in the same way as it has other industries. 

8:55am - 9:40am 45 mins
Info
Cell and Gene Therapy Commercialization
Bioprocessing 4.0 – Digital Technologies Are Transforming Biologics Manufacturing
  • Thomas Seewoester, PhD - Executive Director, Plant Manager, Biogen

Manufacturing processes for biologics have been optimized for the last 100 years. Revolutionary steps in the last 20 years included the introduction of process platforms for monoclonal antibodies, the perfection of large scale fed-batch processes and recently more economic scale-out approaches in single-use systems. Digital technologies in contrast are following a much more rapid and exponential innovation curve. Understanding and leveraging digital technologies, looking beyond the molecule and refining mountains of data into instantaneously and globally available insights and wisdom will be a differentiating factor that is starting to transform our industry in the same way as it has other industries. 

8:55am - 9:40am 45 mins
Info
Pre-clinical and Clinical Development for Cell and Gene Therapies
Bioprocessing 4.0 – Digital Technologies Are Transforming Biologics Manufacturing
  • Thomas Seewoester, PhD - Executive Director, Plant Manager, Biogen

Manufacturing processes for biologics have been optimized for the last 100 years. Revolutionary steps in the last 20 years included the introduction of process platforms for monoclonal antibodies, the perfection of large scale fed-batch processes and recently more economic scale-out approaches in single-use systems. Digital technologies in contrast are following a much more rapid and exponential innovation curve. Understanding and leveraging digital technologies, looking beyond the molecule and refining mountains of data into instantaneously and globally available insights and wisdom will be a differentiating factor that is starting to transform our industry in the same way as it has other industries. 

9:40am - 10:20am 40 mins
Morning Coffee and Networking
10:20am - 10:30am 10 mins
Cell and Gene Therapy Bioprocessing
Chairperson's Opening Remarks
  • Jon A. Rowley, Ph.D. - Chief Executive & Technology Officer, RoosterBio Inc.
10:20am - 10:30am 10 mins
Cell and Gene Therapy Commercialization
Chairperson's Opening Remarks
10:20am - 10:30am 10 mins
Pre-clinical and Clinical Development for Cell and Gene Therapies
Chairperson's Opening Remarks
  • Someet Narang - Associate Director, MedImmune, USA
10:30am - 11:00am 30 mins
Info
Cell and Gene Therapy Bioprocessing
Adopting Various Manufacturing Closed Systems to Gene Modified T Cell Therapies
  • Ali Mohamed - VP, CMC, Immatics, USA
  • Immatics developed a proprietary tumor antigen targets discovery platform, XPRESIDENT®
  • The platform identifies novel tumor-specific targets and TCR candidate. It also screens TCR candidates based on these targets against off-target toxicities in absence of reliable in vivo models
  • Natural and engineered TCRs against these tumor targets have been used in various Immatics’ Adoptive Cellular Therapy programs in “First In Man” clinical trials
  • Extensive process development was carried out using primary T cells derived from multiple healthy donors and cancer patients to optimize each step in the manufacturing of TCR T cells for 3 clinical trials (IMA101, IMA201, IMA202, and IMA203)
  • Manufacturing for engineered TCR T cell therapies has been adapted into 3 different closed systems with for future phases of clinical trials with excellent results
10:30am - 11:30am 60 mins
Info
Cell and Gene Therapy Commercialization
Dual Dialogue: When to make the decision to either insource or outsource
  • Lior Raviv - Vice President of Development, Pluristem Therapeutics Inc.
  • Chris Gemmiti, Ph.D. - Head of Operations, Sentien Biotechnologies Inc.

Talk One: Becoming cell therapy Makers - Opportunities and challenges in “in house” manufacturing of cell therapy products

Confirmed speaker: Lior Raviv, Vice President Development, Pluristem, Israel 


Talk Two: Phase-Appropriate Manufacturing - finding the right balance between internal and external manufacturing as a cell therapy company grows

Confirmed speaker: Chris Gemmiti, VP Operations, Sentien Biotechnologies, Inc., USA 



10:30am - 11:00am 30 mins
Info
Pre-clinical and Clinical Development for Cell and Gene Therapies
The Balancing Act: Engineering vs. Tinkering Platform Processes with GMP Manufacturing in Mind
  • Pratik Jaluria - Executive Director, Process Development and Manufacturing, Adverum, USA

At Adverum, our focus is on bringing innovation to patients in need. With that mindset, we are leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform to identify and develop new therapies. Within Process Development, we have built an adaptable platform process that works across multiple therapeutic constructs, at varying scales. As we continue to develop new products, we are assessing new technologies to refine and improve our platform, while preserving aspects that enable versatility. In this talk, we will review aspects of our platform process and provide insight into potential changes that are under consideration, based on our scale-up experiences.

11:00am - 11:30am 30 mins
Info
Cell and Gene Therapy Bioprocessing
The economics of closed systems – Ensuring reproducibility
  • Ohad Karnieli, Ph.D., MBA - CEO, Atvio Biotech
  • How can showing reproducibility then lead to a more economical scale up or out process?
  • Using closed systems to make facilities more economical
  • How does having a closed system impact autologous manufacturing and how does this affect the design of the plant?
11:00am - 11:30am 30 mins
Info
Pre-clinical and Clinical Development for Cell and Gene Therapies
Developing a scaled process for manufacturing stem cell derived islets
  • Austin Thiel - Senior Principal Scientist, Semma Therapeutics, USA
  • ESCs as starting material, allogeneic approach, selection of clinical line
  • Differentiation optimization Scale-up to bioreactors
  • Raw materials for cGMP manufacturing (evaluation, cost, supply chain)
  •  Path to commercialization
11:30am - 12:00pm 30 mins
Info
Cell and Gene Therapy Bioprocessing
Automation Expert Panel
  • Ohad Karnieli, Ph.D., MBA - CEO, Atvio Biotech
  • Ali Mohamed - VP, CMC, Immatics, USA
  • Lior Raviv - Vice President of Development, Pluristem Therapeutics Inc.
  • Tamara Monesmith - Senior Director, Cellular Process Development, Editas Medicine, USA
  • Tristan Thwaites - Lead Technical Scientist, Cell and Gene Therapy Catapult, UK
  • Case studies/feedback on closed systems in general
  • Is there a need to have closed systems in clean rooms?
  • Process automated sampling
  • What can we learn from automation for MAbs?
  • How do you make thinks connectable between different devices?
  • Automation linked to cost of goods
11:30am - 12:00pm 30 mins
Info
Cell and Gene Therapy Commercialization
Capabilities of blood centres and banks – Could they be CMO’s of the future?
  • Wouter Van t’Hof - Cord Blood Bank Director, Cleveland Cord Blood Centre, USA
  • What are the capabilities of blood centres and the blood banking industries?
  • What is the leverage for them to become CMO’s?
  • What changes need to be made to infrastructure to make this happen?
11:30am - 12:00pm 30 mins
Info
Pre-clinical and Clinical Development for Cell and Gene Therapies
Starting off in the right direction: Developing Phase 1 T-cell therapy Processes with a commercial future
  • Someet Narang - Associate Director, MedImmune, USA

Owing to some remarkable positive clinical responses in blood cancers, the field of T-cell therapy (particularly CAR-T) has attracted the interest of big biopharmaceutical companies. These new ideas, targets and approaches in this field have often germinated in the laboratories of academicians and clinical physicians, who then take them through the proof of concept and Phase 1 studies. However, the processes used in these early stage cell therapy clinical trials can come with liabilities related to process complexity, reagent quality, supply chain, logistics and scalability. These liabilities could later pose enormous hurdles towards commercialization of the product, including sole-source risks and cost of goods. Moreover, due to the complex nature of the product and limited understanding of critical quality attributes, changing unit operations or raw materials at the later stages may lead to product comparability issues. Here we present MedImmune’s approach to minimize these risks by proactively and strategically investing efforts in relevant process development areas and technologies.

12:05pm - 12:35pm 30 mins
Info
Cell and Gene Therapy Bioprocessing
How to support and improve CAR-T process performance through advanced data analytics
  • Anna Persson - Senior Principal Data Scientist, Sartorius Stedim Data Analytics, USA

Often autologous cellular therapies, and CAR-T in particular, present unique challenges in manufacturing due to the variability of the starting material and the unique nature of each batch. So far most manufacturing processes employ a fairly rigid approach that does not compensate for the unique characteristics of the starting material. Drawing on years of experience applying advanced analytics to manufacturing in the biotechnology space, we propose the use of the same off the shelf tools to improve autologous therapies. These tools allow categorization of starting materials, process optimization, flexibility in manufacturing, enhanced real-time fault detection and prediction of critical quality attributes (CQA’s). An overview of benefits, necessary pre-requisites and implementation of advanced analytics in manufacturing safe and effective therapies will be provided.

12:05pm - 12:35pm 30 mins
Info
Cell and Gene Therapy Commercialization
Strategies for creating standardization across the cell and gene therapy industry
  • Jamie Margolis - Director, Product Development Operations, Be The Match BioTherapies, USA

This session will discuss strategies for standardization amongst cell and gene therapy companies, collection and transplant center networks, manufacturers and others. Attendees will learn about critical elements of the supply chain that could be adversely impacted by a lack of standardization, as well as efficiencies that can be gained.

12:05pm - 12:35pm 30 mins
Pre-clinical and Clinical Development for Cell and Gene Therapies
Please more to another track
12:35pm - 1:35pm 60 mins
Networking Luncheon in the Poster & Exhibition Hall
1:35pm - 1:40pm 5 mins
Cell and Gene Therapy Bioprocessing
Chairperson's Opening Remarks
  • Ali Mohamed - VP, CMC, Immatics, USA
1:35pm - 1:40pm 5 mins
Cell and Gene Therapy Commercialization
Chairperson's Opening Remarks
1:35pm - 1:40pm 5 mins
Pre-clinical and Clinical Development for Cell and Gene Therapies
Chairperson's Opening Remarks
  • Someet Narang - Associate Director, MedImmune, USA
1:40pm - 2:40pm 60 mins
Info
Cell and Gene Therapy Bioprocessing
Dual Dialogue: Cost of goods calculations for cell therapy products
  • Nick Timmins, PhD - Vice President, Process Science, Bluerock Therapeutics
  • Boaz Leshem - Vice President, Operations and Manufacturing, Pluristem, Israel

Talk One : Better processes with “better” cells – engineering cells for enhanced manufacturability. 

While much of the focus of gene engineering in the CGT field is on therapeutic activities, synthetic biology presents a significant opportunity to augment our approaches to cell manufacturing.  How might we employ cell engineering strategies to improve product quality, reduce COGs, or better understand and control our manufacturing processes?

Confirmed speaker: Nick Timmins, VP Process Sciences, BlueRock Therapeutics, Canada 

 

Talk Two: Title TBC

Confirmed speaker: Boaz Leshem, Vice President, Operations and Manufacturing, Pluristem, Israel 

1:40pm - 2:10pm 30 mins
Info
Cell and Gene Therapy Commercialization
CDMO Expert led panel: How do you choose your development partner?
  • Chris Gemmiti, Ph.D. - Head of Operations, Sentien Biotechnologies Inc.
  • David Peritt - Chief Technology Officer, Sigilon Therapeutics, USA
  • Wouter Van t’Hof - Cord Blood Bank Director, Cleveland Cord Blood Centre, USA
  • How do you choose your CDMO
  • What capabilities should they have?
  • Centralised manufacturing
  • Regional manufacturing
  • Local manufacturing
  • Considerations for autologous, allogeneic and gene therapy products
  • Tech transfer of processes to new facilities
1:40pm - 2:10pm 30 mins
Info
Pre-clinical and Clinical Development for Cell and Gene Therapies
Low Cost Automation to Drive Efficiency and Reproducibility: Case Studies
  • Shashi Murthy, PhD - Professor of Chemical Engineering & Sherman Center Director, Northeastern University

In basic and preclinical research associated with cell therapy, most cell processing is performed manually, straining resources as well as posing challenges in reproducibility and consistency.  With dendritic cell based therapies as the context, several case studies will be presented to illustrate how simple automation solutions can overcome these constraints as well as help optimize future larger scale process development.

2:10pm - 2:40pm 30 mins
Info
Cell and Gene Therapy Commercialization
Key success factors for planning and building a facility for cell therapies
  • Knut Niss - Chief Technology Officer, Mustang Bio, USA
  • Case Study 
2:10pm - 2:40pm 30 mins
Info
Pre-clinical and Clinical Development for Cell and Gene Therapies
Leveraging Academic and Commercial Contract Manufacturing Organizations to Facilitate Accelerated FDA Approvals
  • Linda Kelley - Senior Member & Cell Therapy Facility Director, Moffitt Cancer Center

The 21st Century Cures Act and the FDA mandate for accelerating the approval process for cellular therapies has impact on the approach to GMP manufacturing for early phase clinical trials. We have embraced an academic and industry partnership to facilitate multicenter clinical trials using Tumor Infiltrating Lymphocytes (TIL) and CAR-T cells for liquid and solid tumors. Through a combination of process improvements intended to shorten product manufacturing time, as well as innovative implementation of GMP practices, we have maximized the contribution of academic and contract manufacturing organizations to support multiple on-going trials intended to receive accelerated FDA approval for a new cellular therapy.

2:40pm - 3:10pm 30 mins
Info
Cell and Gene Therapy Bioprocessing
Scale Up of Pluripotent Stem Cell Manufacturing in Single-Use Bioreactors - Challenges, Insights and Solutions
  • Brian Lee - President, PBS Biotech Inc.
  • Benjamin Fryer - Founder, Pluristyx, Incorporated, USA

Vertical-WheelTM bioreactors can be the enabling single-use technology for large-scale manufacturing of allogeneic cell therapy products such as mesenchymal stem cells (MSCs) and pluripotent stem cells (PSCs).  The unique benefits of a Vertical-Wheel bioreactor include the capability to uniformly suspend anchorage-dependent cells grown on microcarriers (such as MSCs) or aggregates of cells (such as PSCs) in an environment of low hydrodynamic shear stress. Homogeneous distribution of dissipation energy inside the vessel consistently generates uniform PSC aggregates, with optimal aggregate size controlled by adjusting the agitation speed. Having the suspension and size of PSC aggregates be uniform is critical for maximizing cell growth and improving the efficiency of subsequent directed differentiation in a bioreactor. Furthermore, the low shear environment and homogeneous dissipation energy levels are consistent across various sizes of Vertical-Wheel bioreactors ranging from 0.5L to 80L, resulting in true, unparalleled scalability for manufacturing of cell therapy products. High-yield cell culture processes for MSCs and human primary cells grown on microcarriers have been successfully scaled up from laboratory benchtop scale to manufacturing scale in Vertical-Wheel bioreactors. In the case of PSCs, optimal cell aggregate size and pluripotency were also maintained even after multiple passages of cell expansion in laboratory-scale bioreactors, which will allow for cell expansion and differentiation into target cells at larger scales.

2:40pm - 3:10pm 30 mins
Info
Cell and Gene Therapy Commercialization
Industrialization of Viral Vector Manufacturing for Gene Therapies: Challenges and Progress
  • Rachel Legmann - Manager of Cell Culture Process Development Lab and Application Specialist, Pall Corporation
2:40pm - 3:10pm 30 mins
Pre-clinical and Clinical Development for Cell and Gene Therapies
Please more to another track
3:10pm - 3:40pm 30 mins
Afternoon Coffee Break
3:40pm - 4:00pm 20 mins
Cell and Gene Therapy Bioprocessing
It Depends: Understanding the Science and History behind the Regulations
  • Nancy Markovitz - Assoc. Director, Regulatory Affairs CMC, Nantkwest, USA
3:40pm - 4:00pm 20 mins
Cell and Gene Therapy Commercialization
It Depends: Understanding the Science and History behind the Regulations
  • Nancy Markovitz - Assoc. Director, Regulatory Affairs CMC, Nantkwest, USA
3:40pm - 4:00pm 20 mins
Pre-clinical and Clinical Development for Cell and Gene Therapies
It Depends: Understanding the Science and History behind the Regulations
  • Nancy Markovitz - Assoc. Director, Regulatory Affairs CMC, Nantkwest, USA
4:00pm - 4:30pm 30 mins
Info
Cell and Gene Therapy Bioprocessing
Developing a commercially-ready process for viral vector manufacturing
  • John Kerwin - Manufacturing Scientist, Gene Therapy, Biogen, USA
  • What can we apply from the 30+ years of biologics manufacturing?
  • Strategies for developing a validation plan
  • Leveraging platforms to provide manufacturing efficiencies
  • Supply of raw materials and viral banks for low cadence products


4:00pm - 4:30pm 30 mins
Info
Cell and Gene Therapy Commercialization
Developing a commercially-ready process for viral vector manufacturing
  • John Kerwin - Manufacturing Scientist, Gene Therapy, Biogen, USA
  • What can we apply from the 30+ years of biologics manufacturing?
  • Strategies for developing a validation plan
  • Leveraging platforms to provide manufacturing efficiencies
  • Supply of raw materials and viral banks for low cadence products


4:00pm - 4:30pm 30 mins
Pre-clinical and Clinical Development for Cell and Gene Therapies
Current state of play for the cell therapy industry in the clinic – stats and facts
  • Patricia Reilly - Vice President of Intelligence Alliances and Product Unification, Pharma intelligence, Informa
4:30pm - 5:00pm 30 mins
Info
Cell and Gene Therapy Bioprocessing
Strategies to Deliver Scalable and Reliable Lentiviral Vector Biomanufacturing
  • Jeffrey Bartlett - Chief Scientifc Officer, Senior Vice President, Research and Development , Calimmune, Inc., USA

Large-scale clinical production of lentiviral vectors (LV) using current good manufacturing practice (cGMP) methods comes with significant challenges. We have established the CytegrityTM stable cell line system for LV bioproduction and have defined key process, quality and regulatory parameters needed to achieve desired productivity and quality across multiples scales and different bioproduction systems. This approach has allowed scalable bioproduction of LV required for Phase I and II clinical trials, while paving the way for future commercialization.

4:30pm - 5:00pm 30 mins
Info
Cell and Gene Therapy Commercialization
Strategies to Deliver Scalable and Reliable Lentiviral Vector Biomanufacturing
  • Jeffrey Bartlett - Chief Scientifc Officer, Senior Vice President, Research and Development , Calimmune, Inc., USA

Large-scale clinical production of lentiviral vectors (LV) using current good manufacturing practice (cGMP) methods comes with significant challenges. We have established the CytegrityTM stable cell line system for LV bioproduction and have defined key process, quality and regulatory parameters needed to achieve desired productivity and quality across multiples scales and different bioproduction systems. This approach has allowed scalable bioproduction of LV required for Phase I and II clinical trials, while paving the way for future commercialization.

4:30pm - 5:00pm 30 mins
Info
Pre-clinical and Clinical Development for Cell and Gene Therapies
What academia are looking for in a development partner
  • Olive Sturtevant - Administrative Director of Connell & O'Reilly Families, Cell Manipulation Core Facility, Dana Farber Cancer Institute, USA
  • Case study
  • What are academia doing the research looking for in a business partner?
  • How can these partnerships work to drive success?
5:00pm - 5:30pm 30 mins
Info
Cell and Gene Therapy Bioprocessing
Solving challenges in lentiviral vector manufacturing
  • Hanna Leinonen - Senior Scientist, Kuopio Center for Gene and Cell Therapy, Finland

For a long time commercial scale viral vector manufacturing was a bottleneck in the field. Biggest challenges were related to those vectors, such as lentiviral vectors, requiring plasmid transfection of adherent cells in big volumes. We have developed a commercial scale lentiviral vector manufacturing process utilizing PEIpro® based four plasmid transfection and the iCELLis® fixed-bed bioreactor for adherent 293T cells. iCELLis Nano (2.67-4 m2) was used for optimizing several production parameters for scale-up. For scalable LV production, perfusion rate control by measuring cell metabolite concentrations in the bioreactor leads to higher productivity and reduced costs. Optimization of transfection conditions, cell seeding density for targeted cell concentration during transfection, use of low compaction fixed-bed and lowering the culture pH have a positive effect on LV productivity. Developed process was scaled up into iCELLis500 and were able to show the real commercial scale lentiviral vector manufacturing in commercial scale yielding >10^16 viral particles. Commercial scale upstream process development was followed by development of scalable downstream process. Virus containing medium was harvested by perfusion, concentrated and diafiltrated by tangential flow filtration and virus was purified using anion exchange chromatography. These results show for the first time that plasmid transfection of adherent cells in iCELLis bioreactor is scalable from bench level to clinical scale LV production.

5:00pm - 5:30pm 30 mins
Info
Cell and Gene Therapy Commercialization
Solving challenges in lentiviral vector manufacturing
  • Hanna Leinonen - Senior Scientist, Kuopio Center for Gene and Cell Therapy, Finland

For a long time commercial scale viral vector manufacturing was a bottleneck in the field. Biggest challenges were related to those vectors, such as lentiviral vectors, requiring plasmid transfection of adherent cells in big volumes. We have developed a commercial scale lentiviral vector manufacturing process utilizing PEIpro® based four plasmid transfection and the iCELLis® fixed-bed bioreactor for adherent 293T cells. iCELLis Nano (2.67-4 m2) was used for optimizing several production parameters for scale-up. For scalable LV production, perfusion rate control by measuring cell metabolite concentrations in the bioreactor leads to higher productivity and reduced costs. Optimization of transfection conditions, cell seeding density for targeted cell concentration during transfection, use of low compaction fixed-bed and lowering the culture pH have a positive effect on LV productivity. Developed process was scaled up into iCELLis500 and were able to show the real commercial scale lentiviral vector manufacturing in commercial scale yielding >10^16 viral particles. Commercial scale upstream process development was followed by development of scalable downstream process. Virus containing medium was harvested by perfusion, concentrated and diafiltrated by tangential flow filtration and virus was purified using anion exchange chromatography. These results show for the first time that plasmid transfection of adherent cells in iCELLis bioreactor is scalable from bench level to clinical scale LV production.

5:00pm - 5:30pm 30 mins
Pre-clinical and Clinical Development for Cell and Gene Therapies
Discussion Panel: Driving collaboration for development in cell and gene therapy
  • Linda Kelley - Senior Member & Cell Therapy Facility Director, Moffitt Cancer Center
  • Olive Sturtevant - Administrative Director of Connell & O'Reilly Families, Cell Manipulation Core Facility, Dana Farber Cancer Institute, USA
5:30pm - 6:30pm 60 mins
End of Conference Sessions for the Day
6:30pm - 7:30pm 60 mins
Info
Biotech Week Boston Festival Party @ Royale

Don’t miss the Biotech Week Boston Festival Party at The Royale nightclub. This is the only event where you can kick back, and meet attendees from ALL of the official events that are part of Biotech Week Boston. Unwind, network in a fun atmosphere, and enjoy an evening of rock and roll, complete with a headline band.

*This event is free-to-attend for all registered attendees, however space is limited and available on a first-come, first-serve basis.